Calidi Biotherapeutics, Inc. raised approximately $7.5 million by issuing 4,437,869 shares of common stock at $1.69 per share through a public offering, which closed on November 15, 2024. The offering involved a Placement Agency Agreement with Ladenburg Thalmann & Co. Inc., and included lock-up agreements for company executives and directors.